Dr. Wassana Yantasee, CEO, presented an invited talk at the
2021 OHSU Research Week as part of the “Startup Company Showcase”
event in which OHSU startup companies share their compelling stories on bringing
medical technologies to the clinic. PDX Pharma was one of four companies
invited to present.
PDX Pharma is grateful for the support of the BME Department
and […]
PDX Pharmaceuticals received a second round of Series A funding in the amount of $2 million from the Kuni Foundation.
See the press release here
PDX’s CEO and Founder, Wassana Yantasee, PhD commented: “My team and I are excited to embark on this next phase of our clinical development initiatives with the intention of […]
PDX Pharmaceuticals is proud to report that we have filed two international patent applications (PCT) on cancer immunotherapeutics and a provisional application on COVID-19 vaccine today. Protection of intellectual properties (IPs) is our top priority and we work with one of the best IP law firms, Clark+Elbing, Boston, for patent application preparation and prosecution.
– […]
Proud to present PDX Pharma’s new review article in collaboration with OHSU and University of Texas MD Anderson Cancer Center. “Augmenting the therapeutic window of radiotherapy: A perspective on molecularly targeted therapies and nanomaterials” published in Radiotherapy and Oncology.
Highlights
Targeted therapies may augment the therapeutic window of radiotherapy, but toxicities from combining radiation and targeted […]
PDX Pharmaceuticals named Greg Goodwin to its Board of Directors, currently consisting of Drs. Wassana Yantasee and Joe Gray.
Goodwin, a prominent business and community leader, formerly served as the Chief Executive Officer of Kuni Automotive, a Vancouver-based network of fifteen automobile dealerships in five states, including Oregon, Washington, California, Colorado, and Kansas. Goodwin retired […]
PDX Pharmaceuticals was selected to give a company presentation on the topic of “Precision medicine and therapeutic vaccines for cancer” at the Biocom’s 10th Annual Global Life Science Partnering Conference in San Diego on February 26th, 2020. We are grateful to OHSU’s Collaborations and Entrepreneurship program for its support.
PDX Pharmaceuticals received the Series A funding from The Wayne D. Kuni & Joan E. Kuni Foundation, based in Vancouver. This will serve as a matching fund for the phase IIB SBIR award from the NIH (max of $4M) that PDX Pharma is eligible to apply as a phase II SBIR awardee.
PDX Pharmaceuticals’ […]
Drs. Ngamcherdtrakul and Yantasee recently published a
review article “siRNA therapeutics for breast
cancer: recent efforts in targeting metastasis, drug resistance, and immune
evasion” in Translational Research.
In this Review, we describe recent efforts in developing siRNA therapeutics for the treatment of cancer, with particular emphasis on breast cancer. Instead of conventionally targeting proliferation and apoptosis aspects of tumorigenesis, […]
Dr. Wassana Yantasee, President/CEO, serves on scientific review panels for the DOD and NIH in November of 2019; the DOD’s BCRP Clinical & Experimental Therapeutics and the NIH’s SBIR/STTR on Platform Delivery Technologies for Nucleic Acid Therapeutics
Dr. Wassana Yantasee, President/CEO, chaired a session at the Nanotechnologies for Drug Delivery Systems section at the BIT’s 17th Annual Congress of International Drug Discovery Science and Technology-2019 (IDDST-2019) which was held in Kyoto International Conference Center on July 25-27, and gave a talk titled “A versatile nanoparticle platform for targeted delivery of siRNA, chemodrug, […]
Development of antioxidant nanoparticle platform for delivery of siRNA and chemodrugs, Department of Chemistry Seminar Series, Portland State University, May 18th, 2018
Development of a Targeted Therapeutic and Radiation Sensitizer for Lung Cancer, 63rd annual Radiation Research Society (RRS) meeting, Cancun, MX, October 15th, 2017
siRNA-nanoparticles for treating drug-resistant breast cancer, Gordon RNA Technology, Ventura, CA, Feb 1-6. 2015
New methodologies for cancer target identification, personalized medicine in cancer care, and novel therapies based on nanomedicine, BDMS Meeting, Bangkok, Thailand, December 26, 2014 (invited).
OHSU’s effort to understand complex biological systems of cancer leading to targeted therapy with siRNA-nanoparticles, Siriraj School of Medicine, Bangkok, Thailand, December 22, 2014 (invited).
Bioreducible-crosslinked polymer coated mesoporous silica nanoparticles for siRNA targeted delivery to HER2+ breast cancer, 4th International Conference on Nanotek & Expo, San Francisco, CA, December 12, 2014 (invited).
Antibody-conjugated Nanoparticle Platform for Targeted Delivery of SiRNA to HER2+ Breast Cancer, BMES Annual Meeting 2014, San Antonio, TX, October 24, 2014.
SiRNA-mediated Targeting of HER2 as a Viable Approach for Treating Trastuzumab Resistant Breast Cancer, WIN Symposium 2014, Paris, France, June 23, 2014.
Development of a nanoparticle platform for the targeted delivery of siRNA to HER2-positive breast cancers, AACR Annual meeting 2014, San Diego, CA, April 9, 2014.
Nanoparticle Platform for siRNA Delivery with ROS Scavenging Properties for Treating Fibrosis, Keystone Symposium, Fibrosis: From Bench to Bedside (C4), Keystone, CO, March 24, 2014.
Development of a Nanoparticle platform for the Targeted Delivery of siRNA to HER2-positive Breast Cancers, 53rd Annual Meeting and ToxExpo, Society of Toxicology, Phoenix, AZ , March 25, 2014.
Novel Oral Detoxification of Mercury, Cadmium, and Lead with Thiol-Modified Mesoporous Silica, 53rd Annual Meeting and ToxExpo, Society of Toxicology, Phoenix, AZ, March 27, 2014.
Potential Use of Mesoporous Silica Nanoparticle for siRNA Delivery Agent and ROS Scavenger in Fibrotic Diseases, IEEE-Nanomed 2013, Phuket, Thailand, November 11, 2013.
Development of Lanthanide-loaded Mesoporous Silica Nanoparticles for Multi-parametric Single Cell Analysis by Mass Cytometry, IEEE-Nanomed 2013, Phuket, Thailand, November 12, 2013.
Nanoparticle platform for targeted delivery of siRNA and chemotherapies, (keynote presentation), IEEE-Nanomed 2013, Phuket, Thailand, November 12, 2013.
Nanoparticle platform for therapeutic siRNA delivery to HER2 positive breast cancer, TechConnect World 2012 – Nanotech, Santa Clara, CA, June, 2012.